Sensus Healthcare to Host Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call on February 14, 2019

BOCA RATON, Fla., Jan. 30, 2019 Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, February 14, 2019 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year ended December 31, 2018. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

To access the conference call, the dial-in numbers are 855-940-9473 (U.S. Toll Free), 412-317-5220 (International) and 855-669-9657 (Canada Toll Free). Please direct the operator to be connected to the Sensus Healthcare conference call.

Following the conclusion of the conference call, a replay will be available through February 21, 2019 and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 412-317-0088 (International) and 855-669-9658 (Canada Toll Free). All listeners should provide the operator with the following replay access code: 10127952. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time at www.sensushealthcare.com.

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT into its portfolio of treatment devices, the SRT-100™, SRT-100+ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. Sensus also offers Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

For more information, visit http://17s.9e1.myftpupload.com.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/sensus-healthcare-to-host-fourth-quarter-and-full-year-2018-financial-results-and-business-update-conference-call-on-february-14-2019-300786400.html

SOURCE Sensus Healthcare, Inc.

Share this article

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

98.7%+
Non Reoccurrence Rate

No anesthesia, cutting, bleeding, stitching or pain

No downtime or lifestyle restrictions

Super cosmesis, no unsightly scarring

No need for post-treatment reconstructive surgeries

Patient Inquiry

Patient Inquiry

Discover how Sensus Healthcare and the SRT-100TM are removing the physical and emotional pain often associated with skin cancer treatment.
LEARN MORE

Physician Inquiry

Physician Inquiry

Discover how Sensus Healthcare and the SRT-100TM are removing the physical and emotional pain often associated with skin cancer treatment.
LEARN MORE

General Inquiry

General Inquiry

Discover how Sensus Healthcare and the SRT-100TM are removing the physical and emotional pain often associated with skin cancer treatment.
LEARN MORE